secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001104659-22-087893
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q2 net revenue up 20% to $18.3M; loss narrows to $7.5M
----------------------------------------------------------------------

- Net revenue $18.3M (+20% YoY), driven by new product launches despite Targadox generic competition.
- Net loss $7.5M ($0.43/sh) vs. $11.9M ($1.30/sh) in Q2 2021; Adjusted EBITDA loss $2.6M.
- DFD-29 Phase 3 rosacea trials 45% enrolled; top-line data expected H1 2023, NDA in H2 2023.
- Settlement with Padagis solidifies exclusivity for QBREXZA, AMZEEQ, ZILXI; supply chain delays resolved.
- Tenth dermatology product launch planned in H2 2022; salesforce expanded from 42 to 84 reps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922087893/0001104659-22-087893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922087893/tm2222960d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-087893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer